LC-MS/MS method for the characterization of the forced degradation products of Entecavir.

A rapid, specific, and reliable isocratic LC-MS/MS method has been developed and validated for the identification and characterization of the stressed degradation products of Entecavir (ETV). ETV, an antiviral drug, was subjected to hydrolysis (acidic, alkaline, and neutral), oxidation, photolysis and thermal stress, as per the international conference on harmonization specified conditions. The drug showed extensive degradation under oxidative and acid hydrolysis stress conditions. However, it was stable to thermal, acidic, neutral, and photolysis stress conditions. A total of five degradation products were observed and the chromatographic separation of the drug and its degradation products were achieved on a Waters Symmetry C18 (250 mm × 4.6 mm, id, 5 μm) column using 20 mM ammonium acetate (pH 3)/acetonitrile (50:50, v/v) as a mobile phase. The degradation products were characterized by LC-MS/MS and its fragmentation pathways were proposed. The LC-MS method was validated with respect to specificity, linearity, accuracy, and precision. No previous reports were found in the literature regarding the degradation behavior of ETV.

[1]  Q. Sui,et al.  Optimization of mobile phase for the determination of Esomeprazole and related compounds and investigation of stress degradation by LC-MS. , 2013, Journal of separation science.

[2]  P. Solich,et al.  Highly sensitive fast determination of entecavir in rat urine by means of hydrophilic interaction chromatography-ultra-high-performance liquid chromatography-tandem mass spectrometry. , 2012, Journal of chromatography. A.

[3]  S. Yamada,et al.  521 PROSPECTIVE STUDY OF HEPATITIS B VIRUS REACTIVATION IN HBSAG-NEGATIVE PATIENTS AFTER CHEMOTHERAPY WITH RITUXIMAB: HBV-DNA MONITORING AND ENTECAVIR PROPHYLAXIS , 2012 .

[4]  A. Davey,et al.  Salting-out homogeneous liquid-liquid extraction approach applied in sample pre-processing for the quantitative determination of entecavir in human plasma by LC-MS. , 2012, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[5]  X. Zhuo.  PP-101 A dynamic model of entecavir therapy and after therapy for HBV Infection , 2011 .

[6]  B. Chandu,et al.  LC-ESI-MS/MS method for the quantification of entecavir in human plasma and its application to bioequivalence study. , 2011, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[7]  D. R. Nogueira,et al.  Development and validation of a stability-indicating capillary zone electrophoretic method for the assessment of entecavir and its correlation with liquid chromatographic methods. , 2011, Analytical sciences : the international journal of the Japan Society for Analytical Chemistry.

[8]  R. N. Rao,et al.  Separation and characterization of forced degradation products of abacavir sulphate by LC-MS/MS. , 2011, Journal of pharmaceutical and biomedical analysis.

[9]  R. N. Rao,et al.  LC-MS/MS studies of ritonavir and its forced degradation products. , 2010, Journal of pharmaceutical and biomedical analysis.

[10]  W. Koizumi,et al.  Entecavir is an optional agent to prevent hepatitis B virus (HBV) reactivation: a review of 16 patients. , 2010, European journal of internal medicine.

[11]  M. Buti,et al.  Successful use of entecavir for a severe case of reactivation of hepatitis B virus following polychemotherapy containing rituximab. , 2009, Journal of hepatology.

[12]  J. Gale,et al.  A sensitive method for the determination of entecavir at picogram per milliliter level in human plasma by solid phase extraction and high-pH LC-MS/MS. , 2009, Journal of pharmaceutical and biomedical analysis.

[13]  Qing-ling Li,et al.  Dynamics of hepatitis B virus resistance to entecavir in a nucleoside/nucleotide-naïve patient. , 2009, Antiviral research.

[14]  F. LaCreta,et al.  Lack of an Effect of Human Immunodeficiency Virus Coinfection on the Pharmacokinetics of Entecavir in Hepatitis B Virus-Infected Patients , 2008, Antimicrobial Agents and Chemotherapy.

[15]  R. N. Rao,et al.  Isolation and characterization of process related impurities of olanzapine using HPLC and ESI-MS/MS. , 2008, Journal of separation science.

[16]  J. Sasadeusz.  The anti-HIV antiviral activity of entecavir: the loss of a trusted friend? , 2007, Journal of hepatology.

[17]  G. Yao.  Entecavir is a potent anti-HBV drug superior to lamivudine: experience from clinical trials in China. , 2007, The Journal of antimicrobial chemotherapy.

[18]  S. J. Matthews,et al.  Entecavir for the treatment of chronic hepatitis B virus infection. , 2006, Clinical therapeutics.

[19]  A. Rivkin.  A review of entecavir in the treatment of chronic hepatitis B infection , 2005, Current medical research and opinion.

[20]  F. Ziegler,et al.  Radical cyclization studies directed toward the synthesis of BMS-200475 ‘entecavir’: the carbocyclic core , 2003 .

[21]  Y. Wu.  The use of liquid chromatography-mass spectrometry for the identification of drug degradation products in pharmaceutical formulations. , 2000, Biomedical chromatography : BMC.

[22]  A. Streitwieser,et al.  Isotope Effects on Acidity of Deuterated Formic, Acetic, Pivalic, and Benzoic Acids , 1963 .

[23]  G. B. Brown,et al.  Purine N-Oxides. II. The Structure of Adenine N-Oxide1 , 1958 .